Descrizione del progetto
Introduzione della farmacogenomica nella pratica clinica
Solo in Europa, le reazioni avverse uccidono centinaia di migliaia di pazienti ogni anno. Di conseguenza, lo sviluppo della farmacogenomica per personalizzare le terapie e migliorare i risultati dei trattamenti assume una grande importanza. Il progetto PharmGenHUB, finanziato dall’UE, sosterrà gli sforzi di diversi partner universitari, coordinati dall’Istituto di genetica molecolare e ingegneria genetica dell’Università di Belgrado in Serbia, per sviluppare attività di diagnostica, istruzione, formazione e traduzione delle conoscenze in materia di farmacogenomica in soluzioni digitali per applicazioni mediche nella regione dei Balcani occidentali. Il progetto si avvarrà del sequenziamento del DNA ad alto rendimento per identificare coppie di marcatori farmaco-farmacogenomica specifiche della regione dei Balcani occidentali e per progettare strumenti elettronici volti all’individualizzazione del trattamento nella pratica clinica.
Obiettivo
Personalized medicine uses pharmacogenomics (PGX) to individualize therapy upon patients’ unique DNA profiles. With ~200,000 deaths/year in Europe due to adverse drug reactions, it has become an imperative to improve treatment. In Western Balkans (WB), individualization of therapy is done sporadically. IMGGE (Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Serbia) is a pioneer in the PGX in WB. PharmGenHUB will strengthen IMGGE’s PGX R&I potential by exchanging knowledge between IMGGE and EU partnering institutions: University of Patras, Greece (UPAT), University of Ljubljana, Slovenia (UL), University of Trieste, Italy (UNITS). Through collaboration and knowledge sharing with 3 EU partners, IMGGE will become WB central place for PGX diagnostics and R&I, education and trainings, and translation of PGX knowledge into clinically applicable digital solutions. IMGGE’s research project, high-throughput DNA sequencing of WB populations, with support of UPAT and UL, will identify WB specific drug-PGX marker pairs and enable design of electronic tool for better decision-making in clinical practice, electronic PGX assistant for WB (ePGA-WB). iPSC model for validation of novel PGX markers relevant for Europe will be introduced at IMGGE with support of UNITS. IMGGE will renew, reinforce and establish new connections through networking with WB institutions. Project will be realized through short-term visits of IMGGE staff to EU partner institutions, staff exchanges, on-site trainings, experimental laboratory work. Outreach activities will include PGX days, WB conference and joint summer schools. To strengthen research management capacities and administrative skills of IMGGE staff, a research management unit will be established with assistance from UPAT. As focal point of PGX translational research, IMGGE will impact on WB health-care cost benefits and facilitate WB integration to EU-PGX research area through R&I activities and digitalization.
Programma(i)
Meccanismo di finanziamento
HORIZON-CSA - HORIZON Coordination and Support ActionsCoordinatore
11010 Beograd
Serbia